Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 6
Submit an article Journal homepage
58
Views
6
CrossRef citations to date
0
Altmetric
Review

Refining an Alzheimer’s vaccine to avoid an inflammatory response

Mary E Brown University of Toronto, Centre for Research in Neurodegenerative Diseases, Tanz Neuroscience Building, 6 Queen’s Park Crescent West, Toronto, Ontario, M5S 3H2, Canada. [email protected]
,
Kevin A DaSilva University of Toronto, Centre for Research in Neurodegenerative Diseases, Tanz Neuroscience Building, 6 Queen’s Park Crescent West, Toronto, Ontario, M5S 3H2, Canada. [email protected]; University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada
&
JoAnne McLaurin University of Toronto, Centre for Research in Neurodegenerative Diseases, Tanz Neuroscience Building, 6 Queen’s Park Crescent West, Toronto, Ontario, M5S 3H2, Canada. [email protected]; University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada
Pages 809-816 | Published online: 24 Nov 2005

Bibliography

  • CITRON M: Alzheimer's disease: treatments in discovery and development. Nat. Neurosci. (2002) 5(Suppl.):1055–1057.
  • DAVIS KL, SAMUELS SC: In: Pharmacological Management of Neurological and Psychiatric Disorders. Enna SJ, Coyle JT (Eds), McGraw-Hill, New York, USA (1998):267–316.
  • SELKOE D: Alzheimer's disease: genes, proteins, and therapy. PhysioL Rev. (2001) 81:741–766.
  • MCLAURIN J, YANG DS, YIP CM, FRASER PE: Modulating factors in amyloid-beta fibril formation. J. Struct. Biol. (2000) 130:259–270.
  • NASLUND J, HAROUTUNIAN V, MOHS R et al.: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 283:1571–1577.
  • TERRY RD, PECK A, DETERESA R, SCHECHTER R, HOROUPIAN DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann. Neurol (1981) 10:184–192.
  • BRAAK H, BRAAK E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 82:239–259.
  • DICKSON DW, CRYSTAL HA, BEVONA C, HONER W, VINCENT I, DAVIES P: Correlations of synaptic and pathological markers with cognition of the elderly. NeurobioL Aging (1995) 16:285–298.
  • MCLEAN CA, CHERNY RA, FRASER FW et al.: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. NeuroL (1999) 46:860–666.
  • KLEIN WL, KRAFFT GA, FINCH CE: Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. (2001) 24:219–224.
  • GONG Y, CHANG L, VIOLA KL et ed.:Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA (2003) 100:10417–10422.
  • WALSH DN, KLYUBIN I, FADEEVA JV et al.: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 416:535–539.
  • SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
  • ••First report to show that immunisationwith A131–42 results in decreased plaque load in both prevention and treatment paradigms.
  • JANUS C, PEARSON J, MCLAURIN J et al.: Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
  • •Report that demonstrates that decreased amyloid due to immunisation is accompanied by enhanced behaviour.
  • MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982–985.
  • •Simultaneous report in a different mouse model that showed improved cognition.
  • BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid O-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916–919.
  • BACSKAI BJ, KAJDASZ ST, CHRISTIE RH et al.: Imaging of amyloid-13 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. (2001) 7:369–372.
  • WILCOCK DM, GORDON MN, UGEN KE et al.: Number of A0 inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. (2001) 20:731–736.
  • BACSKAI BJ, KAJDASZ ST, MCLELLAN ME et al.: Non-Fc-mediated mechanisms are involved in clearance of amyloid-0 in vivo by immunotherapy. J. Neurosci. (2002) 22:7873–7878.
  • DAS P, HOWARD V LOOSBROCK N et al.: Amyloid-0 immunization effectively reduces amyloid deposition in FcRy-/- knock-out mice. J. Neurosci. (2003) 23:8532–8538.
  • WILCOCK DM, DICARLO G, HENDERSON D et al.: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. (2003) 23:3745–3751.
  • DEMATTOS RB, BALES KR, CUMMINS DJ et al.: Peripheral anti-A(3 antibody alters CNS and plasma A0 clearance and decreases brain A0 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA (2001) 98:8850–8855.
  • SOLOMON B, KOPPEL R, HANAN E et al.: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer O-amyloid peptide. Proc. Natl Acad. Sci. USA (1996) 93:452–455.
  • SOLOMON B, KOPPEL R, FRANKEL D et al.: Disaggregation of Alzheimer O-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA (1997) 94:4109–4112.
  • FRENKEL D, SOLOMON B, BENT-JAR I: Modulation of Alzheimer's 0-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol (2000) 106:23–31.
  • MCLAURIN J, CECAL R, KIERSTEAD ME et al.: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. (2002) 8:1263–1269.
  • BARD F, BARBOUR R, CANNON C et al.: Epitope and isotype specificities of antibodies to 0-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA (2003) 100:2023–2028.
  • DODEL RC, HAMPEL H, DU Y: Immunotherapy for Alzheimer's disease. Lancet Neurol (2003) 2:215–220.
  • SENIOR K: Dosing in Phase II trial of Alzheimer's vaccine suspended. Lancet Neurol (2002) 1:3.
  • ORGOGOZO JM, GILMAN S, DARTIGUES JF et al.: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 61:46–54.
  • ••First indication that severe side effects werepresent in AN-1792 clinical trials.
  • NICOLL JA, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report. Nat. Med. (2003) 9:448–452.
  • •Case report of the first patient that died after the vaccine trial, which shows the decreased extracellular plaque load.
  • FERRER I, BOADA ROVIRA M, SANCHEZ GUERRA ML, REY MJ, COSTA-JUSSA F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 14:11–20.
  • PFEIFER M, BONCRISTIANO S, BONDOLFI Let al.: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 298:1379.
  • ••First report to demonstrate possible sideeffects of passive immunisation, and points to the need to determine CAA load before pursuing this treatment strategy.
  • ODDO S, BILLINGS L, KESSIAK JP, CRIBBS DH, LAFERLA FM: A0 Immunotherapy leads to clearance of early but not late, hyperphosphorylated Tau aggregates via the proteasome. Neuron (2004) 43:321–332.
  • •First attempt to try to link All clearance with changes in tau pathology.
  • BAYER AJ, BULLOCK R, JONES RW et al.: Evaluation of the safety and immunogenicity of synthetic A042 (AN1792) in patients with AD. Neurology (2005) 64:94–100.
  • HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against 0-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38:547–554.
  • FURLAN R, BRAMBILLA E, SAN VITO F et al.: Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain (2003) 126:285–291.
  • MASLIAH E, HANSEN L, ADAME A et al.: A0 vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Ann. Neurol (2005) 64:129–131.
  • •First report to demonstrate similar pathological benefits after AN-1792 vaccination in patients that did not exhibit encephalitis.
  • LOMBARDO JA, STERN EA, MCLELLAN ME et al.: Amyloid-0 antibody treatment leads to rapid 814 normalization of plaque-induced neuritic alterations. J. Neurosci. (2003) 23:10879–10883.
  • FOX NC, BLACK RS, GILMAN S et al.: Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. Neurology (2005) (In Press).
  • GILMAN S, KOLLER M, BLACK RS et al.: Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurology (2005) (In Press).
  • WEINER HL, SELKOE DJ: Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 420:879–884.
  • GRUBECK-LOEBENSTEIN B, BLASKO I, MARX F, TRIEB K: Immunization with beta-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. (2000) 23:114.
  • MONSONEGO A. ZOTA V, KARN A et al.: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer's disease. J. Clin. Invest. (2003) 112:415–422.
  • •Identification of an epitope that is associated with decreased amyloid load and no toxicity.
  • TRIEB K, RANSMAYR G, SGONC R, LASSMANN H, GRUBECK-LOEBENSTEIN B: APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging (1996) 17:541–547.
  • PRIDE MW, BLACK RS, HAGEN M et al.: Evaluation of potential immunologic mechanisms in the pathogenesis of treatment-induced meningoencephalitis in Alzheimer's disease patients treated with AN1792 (QS-21). NeurobioL Aging (2004) 25:574.
  • SEUBERT P, LEE M, BARD F et al.: Characterization of the humoral response to AN1792 immunization in AD patients. Neurobiol Aging (2004) 25:588.
  • SPINNEY L: Update on Elan vaccine for Alzheimer's disease. Lancet Neurol (2004) 3:5.
  • SIGURDSSON EM, SCHOLTZOVA H, MEHTA PD, FRANGIONE B, WISNIEWSKI T: Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. PathoL (2001) 159:439–447.
  • SIGURDSSON EM, KNUDSEN E, ASUNI A et al.: An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-b derivatives. J. Neurosci. (2005) 24:6277–6282.
  • LEVERONE JF, SPOONER ET, LEHMAN HK, CLEMENTS JD, LEMERE CA: Abetal-15 is less immunogenic than Abetal-40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'. Vaccine (2003) 21:2197–2206.
  • AGADJANYAN MG, GHOCHIKYAN A. PETRUSHINA I et al.: Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from 13-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide./ Immunol (2005) 174:1580–1586.
  • NEUROINFLAIVIMATION WORKING GROUP: Inflammation and Alzheimer's disease. NeurobioL Aging (2000) 21:383–421.
  • MONSONEGO A, IMITOLA J, ZOTA V,OIDA T, WEINER HL: Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Thl cells. J. Immunol (2003) 171:2216–2224.
  • LEMERE CA. MARON R, SPOONER ET et al.: Nasal Abeta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. (2000) 920:328–331.
  • WEINER HL, LEMERE CA, MARON R et al.: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. NeuroL (2000) 48:567–579.
  • CRIBBS DH, GHOCHIKYAN A, VASILEVKO Vet al.: Adjuvant-dependent modulation of Thl and Th2 responses to immunization with beta-amyloid. Int. Immunol (2003) 15:505–514.
  • PUAUX AL, MICHEL ML: New gene-based approaches for an AIDS vaccine. Comp. Immunol MicrobioL Infect. Dis. (2003) 26:357–372.
  • FINN 0J: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol (2003) 3:630–640.
  • ZHANG J, XU S, QIN J et al.: A novel recombinant adeno-associated virus vaccine reduces behavioural impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. NeurobioL Dis. (2003) 14:365–379.
  • BOWERS WJ, MASTRANGELO MA, STANLEY HA, CASEY AE, MILO LJ, FEDEROFF HJ: HSV amplicon-mediated Af3 vaccination in Tg2576 mice: differential antigen-specific immune responses. NeurobioL Aging (2005) 26:393–407.
  • GHOCHIKYAN A, VASILEVKO V, PETRUSHINA I et al.: Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur. j Immunol (2003) 33:3232–3241.
  • KIM HD, KONG FK, CAO Y et al.: Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid-13 protein and GM-CSF reduces amyloid load in the brain. Neurosci. Lett. (2004) 370:218–223.
  • QU B, ROSENBURG RN, LIPING L, BOYER PJ, JOHNSTON SA: Gene vaccination to bias the immune response to Amyloid-13 peptide as therapy for Alzheimer's disease. Arch NeuroL (2004) 61: 1859-1864.
  • SCHILTZ JG, SALZER, U, MOHAJERI MH et al.: Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J. MoL Med. (2004) 82:706–714.
  • FRENKEL D, KATZ 0, SOLOMON B et al.: Immunization against Alzheimer's 13-amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA (2000) 97:11455–11459.
  • RACKE MM, BOONE LI, HEPBURN DL et al.: Exacerbation of cerebral amyloid angiopathy-associated microhaemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-13. j Neurosci. (2005) 25:629–636.
  • DODEL RC, DU C, DEPBOYLU C et ell.:Intravenous immunoglobulins containing antibodies against 13-amyloid for the treatment of Alzheimer's disease./ NeuroL Neurosurg. Psychiatry (2004) 75:1472–1474.
  • •Potential for a safe, well-established protocol to be effective for the treatment of AD, and one that might act via multiple mechanisms.
  • RANGAN S, LIU R, BRUNE D et al.: Degradation of 0-amyloid by proteolytic antibody light chains. Biochemistry (2003) 42:14328–14334.

Websites

  • http://www.elan.com/ research_development/Alzheimers/ Elan Alzheimer's Research. Accessed 26 April 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.